Keryx Trims, But Can't Scrap Shareholder Stock-Drop Suit
Keryx Biopharmaceuticals Inc.'s bid to escape a proposed shareholder class action claiming it inflated its stock price by hiding a drug's supply chain problems was rejected by a Massachusetts federal judge,...To view the full article, register now.
Already a subscriber? Click here to view full article